| Metric | Q1-26 | Q1-25 |
|---|---|---|
| Pretax Income | -2.00 | -1.83 |
| Net Income | -2.33 | -1.73 |
| Diluted EPS | -0.42 | -0.44 |
- Net Income YoY
- -35.0%
Key highlights
- Net loss widened by 35.0% year-over-year to $2.33 million in Q1-26
- Pretax income decreased to -$2.00 million from -$1.83 million in the prior-year period
- Diluted earnings per share improved slightly to -$0.42 compared to -$0.44 in Q1-25
- Company reaffirmed expected gross proceeds of $490.0 million from pre-closing financing
- Shareholder vote on the Mentari Therapeutics merger scheduled for November 4, 2026
How the Period Went
InMed Pharmaceuticals reported a net loss of $2.33 million for the first quarter of fiscal 2026, representing a 35.0% expansion in losses compared to the $1.73 million deficit recorded in Q1-25. Pretax losses also increased, reaching $2.00 million for the quarter against $1.83 million in the previous year. Despite the deeper net loss, diluted earnings per share saw a marginal improvement to -$0.42 from -$0.44, likely reflecting changes in the weighted average shares outstanding. The financial results highlight the company's continued transition as a clinical-stage developer with no revenue-generating backlog as of the period end.
Margins and Profitability
The company’s profitability remains constrained by significant research and development outlays required for its cannabinoid-based pipeline. The $0.17 million year-over-year increase in pretax losses underscores the rising costs of clinical trials and the development of proprietary manufacturing technologies. Management is currently focusing on a strategic merger with Mentari Therapeutics to stabilize its long-term financial position. According to company reports from inmedpharma.com, a successful closing is expected to provide a cash runway extending into 2029, a critical factor for a firm currently reporting an operating loss of $2.33 million.
Business Overview
InMed Pharmaceuticals operates within the specialty and generic drug manufacturing sector, focusing on the therapeutic potential of rare cannabinoids. The company utilizes proprietary biosynthetic and manufacturing platforms to develop treatments for diseases with high unmet medical needs. Currently, InMed is at a pivotal corporate juncture; an annual general and special meeting is scheduled for November 4, 2026, to vote on the Mentari Therapeutics merger. This transaction is paired with a record date of November 5, 2026, for the distribution of Contingent Value Rights to existing shareholders, signaling a shift toward a combined entity structure.
Financial Context and Industry Landscape
With a market capitalization of $8.95 million, InMed is navigating the volatile micro-cap biotech space. The stock has demonstrated strong momentum with a 20.74% gain over the last month, though its RSI of 72.7 suggests technical overextension. In the broader cannabinoid pharmaceutical sector, peers are increasingly seeking consolidation to manage high R&D risks. InMed's projected $490.0 million capital infusion upon merger closing would significantly distance it from smaller cash-strapped peers. However, the company must continue to manage its cash position carefully until the targeted merger closing by the end of calendar year 2026.
Up 973.6% since our story on 3 Nov: $1.63 when we broke it → $17.50 at the close on 4 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 5 Oct | $13.30 |
|---|---|
| 6 Oct | $13.30 |
| 7 Oct | $13.30 |
| 8 Oct | $13.30 |
| 9 Oct | $13.60 |
| 12 Oct | $13.60 |
| 13 Oct | $13.30 |
| 14 Oct | $13.10 |
| 15 Oct | $13.30 |
| 16 Oct | $13.20 |
| 19 Oct | $13.65 |
| 20 Oct | $13.40 |
| 21 Oct | $13.60 |
| 22 Oct | $13.30 |
| 23 Oct | $14.40 |
| 26 Oct | $15.90 |
| 27 Oct | $15.90 |
| 28 Oct | $15.99 |
| 29 Oct | $16.25 |
| 30 Oct | $16.00 |
| 2 Nov | $16.30 |
| 3 Nov | $16.80 |
| 4 Nov | $17.50 |
| Date | Announcement | Amount |
|---|---|---|
| 09 Sep 2026 | Q4 and FY 2026 financial resultsSource: inmedpharma.com | – |
| 06 May 2026 | Q3 FY 2026 financial resultsSource: inmedpharma.com | – |
| 11 Feb 2026 | Q2 FY 2026 financial resultsSource: investing.com | $0.8 Million |
| 06 Nov 2025 | Q1 FY 2026 financial resultsSource: investing.com | $1.1 Million |
| 23 Sep 2025 | Q4 and FY 2025 financial resultsSource: investing.com | $1.3 Million |
| 12 May 2025 | Q3 FY 2025 financial resultsSource: investing.com | $1.3 Million |
| Share price | $1.63 |
|---|---|
| Market cap | $9M |
| 1-month price change | +20.74% |
| Sector | HealthcareDrug Manufacturers - Specialty & Generic |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by InMed Pharmaceuticals Inc. announcing its quarterly financial results for the period ended September 30, 2026.
Track InMed Pharmaceuticals Inc. live
Get the next InMed Pharmaceuticals Inc. SEC filing seconds after it lands.



